Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Chimerix Inc
Healthcare
P/NCAV
0.48x
Ticker
CMRX
Exchange
NASDAQ
Country
United States
Close
0.93 $
Mkt Cap
82.0M $
EV
54.3M $
NCAV Burn Rate
17.6%
Current Ratio
10.25
Debt/Equity
0.0
EV/REV
167.67x
EV/EBIT
-0.6x
EV/FCF
-0.8x
Dilution
11.6% p.A
Total Net Income
-632.8M $
Cheapness
99.0%
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company-s product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company-s product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average